NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Herein we report results of a phase I/II trial to evaluate the safety and activity of autologous T-cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing a naturally processed peptide sh...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Rapoport, Aaron P., Stadtmauer, Edward A., Binder-Scholl, Gwendolyn K., Goloubeva, Olga, Vogl, Dan T., Lacey, Simon F., Badros, Ashraf Z., Garfall, Alfred, Weiss, Brendan, Finklestein, Jeffrey, Kulikovskaya, Irina, Sinha, Sanjoy K., Kronsberg, Shari, Gupta, Minnal, Bond, Sarah, Melchiori, Luca, Brewer, Joanna E., Bennett, Alan D., Gerry, Andrew B., Pumphrey, Nicholas J., Williams, Daniel, Tayton-Martin, Helen K., Ribeiro, Lilliam, Holdich, Tom, Yanovich, Saul, Hardy, Nancy, Yared, Jean, Kerr, Naseem, Philip, Sunita, Westphal, Sandra, Siegel, Don L., Levine, Bruce L., Jakobsen, Bent K., Kalos, Michael, June, Carl H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4529359/
https://ncbi.nlm.nih.gov/pubmed/26193344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados